Pharming Group NV is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Pharming Group NV in the market include Biocryst Pharmaceuticals, CSL Behring, Grifols, and Takeda Pharmaceutical Company Limited.

Pharming Group NV is a biopharmaceutical company with a rich history and remarkable background. The company was established in 1988, headquartered in the Netherlands. Pharming focuses on the development and commercialization of innovative protein replacement therapies and precision medicines utilizing its proprietary technology platform. The company is renowned for its pioneering work in the field of recombinant human plasma proteins, particularly Recombinant Human C1 Inhibitor (rhC1INH). Pharming Group NV has successfully developed and marketed these life-saving treatments for hereditary angioedema (HAE) and acquired angioedema (AAE), significantly improving the lives of patients worldwide. With an impressive track record of scientific expertise and substantial market presence, Pharming Group NV continues to be a leading player in the biopharmaceutical industry.

Pharming Group NV has achieved several significant milestones. Notably, the company received approval for its lead product, Ruconest, by regulatory authorities in the United States and Europe. This approval allows Pharming Group NV to market Ruconest for the treatment of acute hereditary angioedema attacks, enhancing the company's market presence. Additionally, Pharming Group NV has successfully expanded Ruconest's sales and commercial footprint, securing distribution agreements in various countries. The company's consistent efforts in research and development have resulted in the exploration of new therapeutic areas, such as Pompe disease. Pharming Group NV's commitment to innovation and attaining regulatory approvals has paved the way for its growth and success in the biopharmaceutical industry.

Pharming Group NV is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates its North American headquarters. Additionally, Pharming Group NV has a significant presence in Europe, with offices and distribution networks in various countries such as the Netherlands, Germany, France, Italy, and the United Kingdom. Furthermore, the company has expanded its reach into Asia, particularly in important markets like Japan and South Korea. With its global presence, Pharming Group NV is able to effectively deliver its innovative biopharmaceutical products and therapies to patients across different continents.

Pharming Group NV represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Pharming is committed to developing innovative therapies for patients with unmet medical needs. They prioritize collaboration by partnering with research institutions, healthcare professionals, and patient organizations to advance scientific knowledge. Pharming's corporate philosophy revolves around improving the quality of life for patients through the development and commercialization of novel therapies. Their dedication to scientific excellence, integrity, and global outreach enables them to provide effective and life-changing therapies for patients around the world.

Analysts currently set an average price target of 2,53 USD for the Pharming Group stock (median: 2,35 USD), implying +96,1 % versus the latest price. The consensus is based on 14 analyst ratings.

Pharming Group Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Pharming Group stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pharming Group to generate revenue of 407,28 M USD and earnings per share of 0,02 USD.

Pharming Group Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Pharming Group share trades at 1,12 EUR (1,29 USD).

The Pharming Group share (PHARM.AS) is listed on 9 stock exchanges, including: Frankfurt (PHGN.F), München (PHGN.MU), Düsseldorf (PHGN.DU), London (0QCO.L), SIX (Zürich) (PHGN.SW), Amsterdam (PHARM.AS).

The Pharming Group NV is a biopharmaceutical company specialized in the development of innovative therapies for rare genetic diseases. The company is based in Leiden, Netherlands and is listed on the Euronext Amsterdam exchange. Pharming's business model is based on the research and development of biopharmaceuticals for the treatment of rare genetic diseases. The company focuses particularly on rare immune system disorders, including Hereditary Angioedema (HAE) and Lymphocytic Varicosis (LV). Pharming also conducts clinical trials for the treatment of other rare diseases. Pharming's products include Ruconest, a recombinant C1 esterase inhibitor (rhC1INH) used for the treatment of HAE. Ruconest is Pharming's flagship product and is marketed globally. The company has also developed a biosimilar version of Ruconest, which is produced under the brand name RucON. Pharming also has a pipeline of future products in development, including a recombinant factor VIII for the treatment of Hemophilia A and a recombinant factor IX for the treatment of Hemophilia B. The company is also working on the development of therapies for the treatment of rarer diseases such as Vascular Ehlers-Danlos Syndrome (EDS). Pharming pursues a diversified business model with a focus on research and development, production, and marketing of biopharmaceuticals. The company also operates its own manufacturing facility to ensure the production of biopharmaceuticals. Pharming also follows a strategic acquisition strategy to expand its product pipeline and increase market presence. Pharming's business model is based on a strong research and development pipeline, efficient production, a differentiated product range, and a strong marketing strategy to increase its presence in the markets. Pharming's focus on rare genetic diseases and continuous innovation in the treatment of these diseases make the company an important player in the biopharmaceutical market.

odotettu liikevaihto Pharming Group on 407,28 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Pharming Group on 17,11 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Pharming Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 57,17. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pharming Group-osakkeen arvostusta.

Pharming Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,40. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pharming Group-osakkeen arvostuskennuslukuna.

Pharming Group:n Eulpool-laatuscore on 5/10.

Pharming Group:n ISIN on NL0010391025. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Pharming Group:n WKN on A1H65A. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Pharming Group:n ticker on PHARM.AS. Tämä pörssinoteeraus käytetään Pharming Group-osakkeiden kauppaan pörssissä.

Pharming Group maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Pharming Group kuuluu sektoriin 'Terveydenhuolto'.

Pharming Group:n osingot jaetaan valuutassa USD.